Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Drue Ferrante

Internal Medicine Gainesville, FL Medical Doctor

NPI 1265427165 CMS profile 329073

1130 Nw 64Th Ter, Gainesville, FL 32605

Open in the dashboard

General payments

$9,523

440 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Drue Ferrante of Gainesville, FL is reported in the CMS Open Payments database as having received $9,523 across 440 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,662 76
2024 General $1,690 68
2023 General $1,693 79
2022 General $1,872 92
2021 General $1,116 51
2020 General $609 33
2019 General $880 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Drue Ferrante
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Drue Ferrante were reported at $1,662. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Drue Ferrante Internal Medicine median Middle half National median
2019 $880 $159 $48–$570 $163
2020 $609 $119 $33–$402 $114
2021 $1,116 $135 $37–$521 $132
2022 $1,872 $141 $42–$496 $149
2023 $1,693 $149 $45–$519 $160
2024 $1,690 $154 $47–$537 $164
2025 $1,662 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,504 107 payments
  2. Amgen Inc. $1,154 55 payments
  3. Lilly USA, LLC $1,042 57 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $754 33 payments
  5. AstraZeneca Pharmaceuticals LP $676 14 payments
  6. Pfizer Inc. $633 38 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $391 13 payments
  8. AbbVie, Inc. $330 15 payments
  9. Amarin Pharma Inc. $247 9 payments
  10. Esperion Therapeutics, Inc. $204 5 payments
  11. Other $2,590 94 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,517 439 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $1,081 80 payments
  2. RYBELSUS $970 76 payments
  3. EVENITY $775 30 payments
  4. FARXIGA $653 13 payments
  5. MOUNJARO $584 29 payments
  6. JARDIANCE $520 25 payments
  7. ELIQUIS $452 26 payments
  8. NURTEC ODT $418 26 payments
  9. Prolia $406 25 payments
  10. Kerendia $391 13 payments
  11. Other $6,527 312 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 107 drugs

Part D claims

5,773

Median for Internal Medicine: 777

Drug cost

$352,304

Median for Internal Medicine: $73,373

Branded share of claims

18.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 55 $60,737
Mounjaro Tirzepatide Brand 38 $45,834
Eliquis Apixaban Brand 39 $41,711
Jardiance Empagliflozin Brand 31 $33,786
Farxiga Dapagliflozin Propanediol Brand 23 $20,880
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 16 $19,462
Spiriva Respimat Tiotropium Bromide Brand 11 $14,614
Aimovig Autoinjector Erenumab-Aooe Brand 19 $13,110
Synthroid Levothyroxine Sodium Brand 81 $6,954
Spiriva Handihaler Tiotropium Bromide Brand 13 $6,768

The 10 drugs with the highest cost, of 107 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$254,579

Of which drugs: $75,734

Medicare patients

454

Average age 75

Services billed

9,924

360 women, 94 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 49%
Diabetes 24%
Ischemic heart disease 22%
Cancer 20%
Osteoporosis 19%
Depression 15%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 28 2,880 $57,852
Vaccine for influenza for injection into muscle 90653 Office 72 72 $5,809
Pcv20 vaccine im 90677 Office 18 18 $5,239
Vaccine for influenza for injection into muscle 90662 Office 39 39 $3,191

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $99
  • Boehringer Ingelheim Pharmaceuticals, Inc. $67
$166 31 —
MOUNJARO
  • Lilly USA, LLC $165
$165 38 —
ZEPBOUND
  • Lilly USA, LLC $148
$148 — —
Wegovy
  • Novo Nordisk Inc $144
$144 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $141
$141 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

440 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record